Skip to main content
Vai all'homepage della Commissione europea (si apre in una nuova finestra)
italiano it
CORDIS - Risultati della ricerca dell’UE
CORDIS

Unlocking a T cell-mediated Immune response in therapy-challenged Tumors

Descrizione del progetto

Approfondimenti sul microambiente tumorale per una terapia duratura

Il microambiente tumorale (TME) si riferisce all’ambiente complesso e dinamico che circonda un tumore e che comprende vari tipi di cellule, componenti della matrice extracellulare e molecole di segnalazione. Il TME svolge un ruolo critico nella progressione del tumore, nelle risposte immunitarie e nell’efficacia del trattamento. Il progetto UnlockIT, finanziato dal CER, intende studiare la complessa biologia del TME sottoposta a sfida terapeutica, nella speranza di svelare i meccanismi di resistenza ai farmaci e di fuga immunitaria. Inoltre, lo studio si concentrerà sull’elaborazione e la presentazione dell’antigene nel TME, con l’obiettivo di rendere le cellule tumorali più visibili al sistema immunitario. L’idea alla base di UnlockIT è quella di fornire le conoscenze fondamentali necessarie per sviluppare terapie antitumorali combinate con effetto duraturo.

Obiettivo

Immuno- and targeted therapies have revolutionized the treatment of cancer patients, and more innovative therapeutics, such as KRAS inhibitors (KRASi), are entering the clinic. However, their use as monotherapies fails to achieve durable tumor control in most patients, and the development of combination therapies remains challenging without an understanding of the complex and dynamic biology that unfolds upon therapeutic challenge in the tumor microenvironment (TME). Most of our knowledge on combination therapies is based on primary, treatment-naïve tumors, but how signaling networks of cancer cells and their interactions with immune cells evolve under therapeutic challenge over time is poorly understood, and strategies to overcome immune-evasive TMEs are lacking. Here, we build on our expertise in modeling the dynamic changes of cancer cells in all phases of therapy to move towardsstrategic, mechanism-based combination therapies.
Our vision is to Unlock a T cell-mediated Immune response in therapy-challenged Tumors, “UnlockIT”, to achieve durable therapy responses in cancer patients. (1) We will use our improved molecular time machine, CaTCHseq, together with novel KRASi and unique KRAS-driven tumor models to understand tumor-TME co-evolution under KRASi and related mechanisms of drug-resistance. (2) We will characterize mediators of antigen processing and presentation in treatment naïve, therapy-challenged and immune evasive cancer cell states by using state-of-the-art genome-wide CRISPR/Cas9 screens in combination with innovative phenotypic readouts. This approach offers a sought-after opportunity to uncover mechanisms that make cancer cells “visible” to immunity. (3) Finally, we aim to overcome immune-evasive TMEs by understanding and targeting antigen-presenting cells in the TME. Taken together, UnlockIT will provide new mechanistic links between oncogenic pathways and immunity, and thereby establish a rational basis for combining targeted and immunotherapies.

Campo scientifico (EuroSciVoc)

Programma(i)

Argomento(i)

Meccanismo di finanziamento

HORIZON-ERC - HORIZON ERC Grants

Vedi tutti i progetti finanziati nell’ambito di questo schema di finanziamento

Invito a presentare proposte

(si apre in una nuova finestra) ERC-2023-COG

Vedi tutti i progetti finanziati nell’ambito del bando

Istituzione ospitante

FORSCHUNGSINSTITUT FUR MOLEKULARE PATHOLOGIE GESELLSCHAFT MBH
Contributo netto dell'UE
€ 2 000 000,00
Indirizzo
CAMPUS-VIENNA-BIOCENTER 1
1030 Wien
Austria
Regione
Ostösterreich Wien Wien
Tipo di attività
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Collegamenti
Costo totale
€ 2 000 000,00

Beneficiari (1)